Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® MRSA specialty page provides MRSA-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


What Makes Eravacycline a Unique Antibiotic?
Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.
Who is Not a Good Candidate for MRSA Prodrug TXA709?
Daniel Pilch, PhD, explains which patients would not make good candidates for MRSA prodrug TXA709.
Developing New Antibiotics: What's the Best Approach to Take?
Daniel Pilch, PhD, discusses the approach that he and his team took to develop a new drug to fight MRSA.
What Are the Special Properties of MRSA Prodrug TXA709?
Edmond LaVoie, PhD, describes the properties of prodrug TXA709.
Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
What is the Role of Combination Therapy in Treating <i>S. aureus</i> Infections?
Prof. Josh Davis, MBBS, PhD, discusses the role of combination therapy when it comes to treating invasive Staphylococcus aureus infections.
Examining the Bactericidal Behavior of a New MRSA Treatment
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains the bactericidal behavior of TXA709, a new drug to treat MRSA infections.
How Does TXA709 Target MRSA?
Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.
We break down our top HIV news stories of 2017. Did you read them all?